Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
In Vivo. 2020 Jul-Aug;34(4):1921-1929. doi: 10.21873/invivo.11989.
BACKGROUND/AIM: This study aimed to seek clinical biomarkers of nivolumab monotherapy for advanced gastric cancer (AGC) of which efficacy is limited. We focused on Glasgow Prognostic Score (GPS), which reflects systemic inflammatory and nutritional status as well as disease control by chemotherapy immediately before nivolumab (DCBC).
AGC patients with measurable lesions who were treated with nivolumab in the third- or later-line were included. DCBC was defined as a best overall response of complete response (CR), partial response, stable disease, or non-CR/non-progressive disease achieved by chemotherapy immediately before nivolumab.
Eighty patients were analyzed. Among the various clinical factors, multivariable analysis revealed that a GPS of 2 was significantly associated with a shorter overall survival and DCBC was significantly associated with a longer progression-free survival.
We present the potential of GPS and DCBC as efficient biomarkers of nivolumab for AGC, that warrants further evaluation.
背景/目的：本研究旨在寻找纳武利尤单抗单药治疗疗效有限的晚期胃癌（AGC）的临床生物标志物。我们重点关注格拉斯哥预后评分（GPS），它反映了化疗前即刻的全身炎症和营养状况以及疾病控制情况。
纳入了接受纳武利尤单抗三线或后线治疗的可测量病变的 AGC 患者。DCBC 定义为化疗前即刻通过化疗实现的完全缓解（CR）、部分缓解、疾病稳定或非 CR/非进展性疾病的最佳总体缓解。
对 80 名患者进行了分析。在各种临床因素中，多变量分析显示，GPS 为 2 与总生存期更短显著相关，而 DCBC 与无进展生存期更长显著相关。
我们提出了 GPS 和 DCBC 作为纳武利尤单抗治疗 AGC 的有效生物标志物的潜力，值得进一步评估。
